Company Overview of NuRx Pharmaceuticals, Inc.
NuRx Pharmaceuticals, Inc. focuses on nuclear receptor target therapeutics for the treatment of cancer. The company’s lead compound, NRX 5183 is in the phase II clinical trial for the treatment of Relapsed Acute Promyelocytic Leukemia. It has a license agreement with Vitae Pharmaceuticals, Inc. to license certain compounds and nuclear receptor technology for human and veterinary use. The company has a joint venture agreement with QuantRX Biomedical Corporation to commercialize point-of-care products. NuRx Pharmaceuticals, Inc. was formerly known as Quest Group International Inc. and changed its name to NuRx Pharmaceuticals, Inc. in October 2007. The company was founded in 2001 and is based i...
18 Technology Drive
Irvine, CA 92618
Founded in 2001
Key Executives for NuRx Pharmaceuticals, Inc.
Chief Executive Officer, President and Director
Executive Director and Member of Nominating Committee
Chief Medical Officer and Member of the Scientific Advisory Board
Secretary, Director, Member of Audit Committee, Member of Nominating Committee and Member of Compensation Committee
Director of Clinical Affairs
Compensation as of Fiscal Year 2014.
NuRx Pharmaceuticals, Inc. Key Developments
SEC Revokes Registration Of Registered Securities Of NuRx Pharmaceuticals
Jul 11 14
An Administrative Law Judge has issued an Initial Decision of Default as to NuRx Pharmaceuticals, Inc. The Initial Decision found that the company was issuer of securities registered pursuant to Section 12(g) of the Securities Exchange Act of 1934 (Exchange Act), and the company failed to comply with Section 13(a) of the Exchange Act and Exchange Act Rules 13a-1 and/or 13a-13 by not filing required periodic reports with the Securities and Exchange Commission (SEC). The Initial Decision finds these allegations to be true and revokes the registration of each class of the company’s registered securities, pursuant to Section 12(j) of the Securities Exchange Act of 1934.
SEC Orders Hearings On Registration Suspension Or Revocation Against NuRx Pharmaceuticals, Inc. For Failure To Make Required Periodic Filings
Jun 11 14
Securities and Exchange Commission (SEC or the commission) instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of NuRx Pharmaceuticals, Inc. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries